Cohrs, Stefan

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Meier, A."],["dc.contributor.author","Neumann, A. C."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Huther, G."],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Cohrs, Stefan"],["dc.date.accessioned","2018-11-07T10:56:36Z"],["dc.date.available","2018-11-07T10:56:36Z"],["dc.date.issued","2005"],["dc.format.extent","263"],["dc.identifier.isi","000232591900169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50052"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","24th Symposium of the Arbeitsgemeinschaft-fur-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Reduced cortisol excretion in healthy subjects under treatment with ziprasidone"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","414"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Psychopharmacology"],["dc.bibliographiccitation.lastpage","420"],["dc.bibliographiccitation.volume","174"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Pohlmann, K."],["dc.contributor.author","Guan, Zhenghua"],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Meier, A."],["dc.contributor.author","Huether, Gerald"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.date.accessioned","2018-11-07T10:47:56Z"],["dc.date.available","2018-11-07T10:47:56Z"],["dc.date.issued","2004"],["dc.description.abstract","Rationale. Hypothalamic-pituitary-adrenal (HPA) axis dysfunction is a frequent finding in psychiatric disorders, including psychotic depression and schizophrenia. Conflicting results exist concerning the influence of antipsychotics on the HPA-axis. Objective. Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the effect of quetiapine on nocturnal urinary cortisol and melatonin excretion in 13 healthy male subjects under conditions of undisturbed and experimentally disturbed sleep. Methods. Volunteers were studied 3 times for 3 consecutive nights (N0, adaptation; N1, standard sleep conditions; N2, acoustic stress) 4 days apart. Placebo, quetiapine 25 mg or quetiapine 100 mg was administered orally 1 h before bedtime on nights 1 and 2. Urine produced during the 8-h bedtime period was collected for later determination of cortisol and melatonin concentrations by standard radioimmunoassays. Results. MANOVA showed a significant effect for N1 vs. N2 with elevated total amount of cortisol (p<0.005) and melatonin (p<0.05) excretion after acoustic stress. Both quetiapine 25 mg and 100 mg significantly (p<0.0005) reduced the total amount of cortisol excretion in comparison to placebo. No interaction effect of stress condition was observed. There was no effect of quetiapine on melatonin levels. Conclusion. The significant reduction of nocturnal cortisol excretion following quetiapine reflects a decreased activity of the HPA-axis in healthy subjects. This finding may be an important aspect in quetiapine's mode of action in different patient populations."],["dc.identifier.doi","10.1007/s00213-003-1766-6"],["dc.identifier.isi","000222646700013"],["dc.identifier.pmid","14735295"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48081"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0033-3158"],["dc.title","Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","11"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Psychopharmacology"],["dc.bibliographiccitation.lastpage","18"],["dc.bibliographiccitation.volume","185"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Roher, C."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Meier, A."],["dc.contributor.author","Huether, Gerald"],["dc.contributor.author","Wuttke, Wolfgang"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.date.accessioned","2018-11-07T10:16:09Z"],["dc.date.available","2018-11-07T10:16:09Z"],["dc.date.issued","2006"],["dc.description.abstract","Rationale: Increased activity of the hypothalamic-pituitary-adrenal (HPA) axis is an important aspect of the pathophysiology of major depression and schizophrenia. Despite the usefulness of atypical antipsychotics in the treatment of depression and their positive influence on cognitive functioning possibly related to their impact on cortisol, little is known about their effect on HPA axis function. Objective: Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the influence of the atypical antipsychotics quetiapine and olanzapine in comparison with haloperidol and placebo on plasma adrenocorticotropic hormone (ACTH), cortisol, and prolactin levels. Eleven healthy male volunteers were studied during four sessions one week apart, orally receiving placebo, quetiapine (50 mg), olanzapine (5 mg), or haloperidol (3 mg). Blood samples were taken at hourly intervals from 0900 until 1700 hours. For ACTH, cortisol, and prolactin a significant effect of treatment condition (p <= 0.005; p <= 0.035; p <= 0.0001, respectively) for area under the curve (AUC) was found. In comparison to placebo, quetiapine and olanzapine significantly reduced ACTH (p <= 0.002; p <= 0.05, respectively) and cortisol (p <= 0.005; p <= 0.03, respectively). No effect of haloperidol on AUC of ACTH or cortisol levels was observed. In comparison with placebo, haloperidol (p <= 0.0001) and olanzapine (p <= 0.0001) elevated AUC of prolactin plasma levels, whereas no significant effect was observed for quetiapine as a main effect of treatment condition. The atypical antipsychotics' strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals' blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. The observed HPA-axis down-regulation may be clinically important for the atypicals' effects on depressive symptomatology and cognitive functioning."],["dc.identifier.doi","10.1007/s00213-005-0279-x"],["dc.identifier.isi","000235547600002"],["dc.identifier.pmid","16432682"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40980"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0033-3158"],["dc.title","The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Guan, Z."],["dc.contributor.author","Pohlmann, K."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Meier, A."],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T10:36:45Z"],["dc.date.available","2018-11-07T10:36:45Z"],["dc.date.issued","2003"],["dc.format.extent","217"],["dc.identifier.isi","000186262800047"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45399"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","23rd Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","MUNICH, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Quetiapine improves sleep quality in healthy subjects"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","421"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Psychopharmacology"],["dc.bibliographiccitation.lastpage","429"],["dc.bibliographiccitation.volume","174"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Guan, Zhenghua"],["dc.contributor.author","Pohlmann, K."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Meier, A."],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T10:47:56Z"],["dc.date.available","2018-11-07T10:47:56Z"],["dc.date.issued","2004"],["dc.description.abstract","The aim of this study was to investigate the effects of quetiapine, an atypical antipsychotic, on polysomnographic sleep structure and subjective sleep quality. This double-blind, placebo-controlled, randomized cross-over study investigated the polysomnographic sleep structure and subjective sleep quality of 14 healthy male subjects given placebo, quetiapine 25 mg or quetiapine 100 mg. Volunteers were studied 3 times for 3 consecutive nights (N0, adaptation; N1, standard sleep conditions; N2, acoustic stress) 4 days apart. Treatment was administered orally 1 h before bedtime on nights 1 and 2. Quetiapine 25 mg and 100 mg significantly improved sleep induction and continuity under standard and acoustic stress conditions. Increases in total sleep time, sleep efficiency, percentage sleep stage 2 and subjective sleep quality were seen. A significant increase in periodic leg movements during sleep was observed with quetiapine 100 mg. The sleep-improving properties of quetiapine may be important in counteracting different aspects of psychopathology in schizophrenia and other disorders. These sleep-inducing and sleep-modifying properties are probably related to quetiapine's receptor-binding profile, including its antihistaminergic, antidopaminergic and antiadrenergic properties. Other mechanisms might be relevant as well and further investigation is required."],["dc.identifier.doi","10.1007/s00213-003-1759-5"],["dc.identifier.isi","000222646700014"],["dc.identifier.pmid","15029469"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48082"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0033-3158"],["dc.title","Sleep-promoting properties of quetiapine in healthy subjects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Meier, A."],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Kornhuber, Johannes"],["dc.contributor.author","Bleich, Stefan"],["dc.date.accessioned","2018-11-07T10:56:34Z"],["dc.date.available","2018-11-07T10:56:34Z"],["dc.date.issued","2005"],["dc.format.extent","252"],["dc.identifier.isi","000232591900119"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50044"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","24th Symposium of the Arbeitsgemeinschaft-fur-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","239"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neural Transmission"],["dc.bibliographiccitation.lastpage","254"],["dc.bibliographiccitation.volume","113"],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Meier, A."],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Kornhuber, Johannes"],["dc.contributor.author","Bleich, Stefan"],["dc.date.accessioned","2018-11-07T10:23:16Z"],["dc.date.available","2018-11-07T10:23:16Z"],["dc.date.issued","2006"],["dc.description.abstract","Assessment of reactive oxygen species (ROS) is highly important in neurodegenerative disorders and neuroleptic treatment. However, conflicting results have been reported, which may arise from methodological difficulties. Obstructive sleep apnea (OSA) syndrome with episodic hypoxia-reoxygenation is proposed as a human model for the investigation of ROS measurements. Despite a broad analytical approach comprising lipid peroxidation and amino acid oxidation products, oxidative DNA damage, and activity of the antioxidant defense, only plasma malondialdehyde (MDA) and urinary o,o'-dityrosine seemed to be appropriate, robust biomarkers of oxidative stress, which are also simple enough for routine clinical use. MDA concentrations correlated with a duration of nocturnal desaturation below 85% (r = 0.77, p < 0.0005), and o,o'-dityrosine levels decreased after therapy (p < 0.05) as a function of baseline concentrations (r = -0.61, p < 0.05). Gender effects in ROS generation also have to be considered. At present, we recommend the application of several oxidative stress measurements at different time points, preferably involving plasma MDA and urinary o,o'-dityrosine."],["dc.identifier.doi","10.1007/s00702-005-0316-2"],["dc.identifier.isi","000234752500013"],["dc.identifier.pmid","15959848"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42424"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0300-9564"],["dc.title","Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Guan, Z."],["dc.contributor.author","Pohlmann, K."],["dc.contributor.author","Jordon, W."],["dc.contributor.author","Meier, A."],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T10:36:45Z"],["dc.date.available","2018-11-07T10:36:45Z"],["dc.date.issued","2003"],["dc.format.extent","217"],["dc.identifier.isi","000186262800046"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45398"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","23rd Symposium of the Arbeitsgemeinschaft-Neuropsychopharmakologie-und-Pharmakopsychiatrie (AGNP)"],["dc.relation.eventlocation","MUNICH, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Cortisol-reducing properties of quetiapine in healthy subjects under an undisturbed and an acoustic stress condition"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","989"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","The Journal of Clinical Psychiatry"],["dc.bibliographiccitation.lastpage","996"],["dc.bibliographiccitation.volume","66"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Meier, A."],["dc.contributor.author","Neumann, A. C."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.date.accessioned","2018-11-07T10:57:16Z"],["dc.date.available","2018-11-07T10:57:16Z"],["dc.date.issued","2005"],["dc.description.abstract","Objective: Ziprasidone, an atypical antipsychotic, is a potent dopamine (D-2) and serotonin (5-HT2A/C) receptor blocker, has agonistic properties at the 5-HT1A receptor, and blocks serotonin and norepinephrine reuptake. These transmitter systems are closely related to the regulation of sleep. Method: The aim of this double-blind, placebo-controlled, randomized, crossover study was to investigate the effects of ziprasidone on polysomnographic sleep structure and subjective sleep quality. Twelve healthy male subjects were randomly assigned to receive ziprasidone 40 mg or placebo for 2 sessions each composed of 2 consecutive nights (night 1, standard sleep conditions; night 2, acoustic stress) 5 days apart. Treatment was administered orally 2 hours before bedtime. The study was conducted from April 2004 to July 2004. Results: Ziprasidone significantly increased total sleep time, sleep efficiency, percentage of sleep stage 2, and slow wave sleep; decreased the number of awakenings; and significantly affected tonic and phasic REM sleep parameters, i.e., it decreased percentage of REM and REM density and profoundly increased REM latency. Conclusion: Ziprasidone's effects on the sleep profile are somehow opposite to what is known about sleep of depressed patients (e.g., disturbances of sleep continuity, a reduciton of slow wave sleep, and a disinhibition of REM sleep). Its REM sleep-suppressing properties resemble those of most, although not all, antidepressants and may be clinically relevant. The drug also demonstrates sleep-consolidating properties under both standard routine and acoustic stress conditions. These effects are most likely related to ziprasidone's 5-HT2C antagonism, 5-HT1A agonism, and serotonin and norepinephrine reuptake inhibition."],["dc.identifier.isi","000231341400005"],["dc.identifier.pmid","16086613"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50204"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Physicians Postgraduate Press"],["dc.relation.issn","0160-6689"],["dc.title","Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: A randomized, controlled, crossover trial of 12 healthy male subjects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","154"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.lastpage","155"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Gade, Katrin"],["dc.contributor.author","Meier, A."],["dc.contributor.author","Jordan, W."],["dc.contributor.author","Falkai, Peter Gaston"],["dc.contributor.author","Ruether, Eckhart"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.date.accessioned","2018-11-07T08:42:59Z"],["dc.date.available","2018-11-07T08:42:59Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.1055/s-0030-1248312"],["dc.identifier.isi","000279668300008"],["dc.identifier.pmid","20205075"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19839"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0176-3679"],["dc.title","Quetiapine Improves Sleep Disturbance in Acute Bipolar Disorder: A Case Series"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]